Imagawa A, Hanafusa T, Miyagawa J, Matsuzawaet Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med. 2000;342(5):301–7. https://doi.org/10.1056/NEJM200002033420501.

Article  CAS  PubMed  Google Scholar 

Imagawa A, Hanafusa T, Awata T, Ikegami H, Uchigata Y, Osawa H, et al. Report of the committee of the Japan diabetes society on the research of fulminant and acute-onset type 1 diabetes mellitus: New diagnostic criteria of fulminant type 1 diabetes mellitus (2012). J Diabetes Investig. 2012;3(6):536–9. https://doi.org/10.1111/jdi.12024.

Article  PubMed  PubMed Central  Google Scholar 

Imagawa A, Hanafusa T. Fulminant type 1 diabetes-East and West. J Clin Endocrinol Metab. 2023;108(12):e1473–8. https://doi.org/10.1210/clinem/dgad329.

Article  PubMed  Google Scholar 

Clotman K, Janssens K, Specenier P, Weets I, De Blocket CEM. Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus. J Clin Endocrinol Metab. 2018;103(9):3144–54. https://doi.org/10.1210/jc.2018-00728.

Article  PubMed  Google Scholar 

Shimada A, Ikegami H. Twenty years since the discovery of fulminant type 1 diabetes. Diabetol Int. 2020;11(4):309. https://doi.org/10.1007/s13340-020-00464-4.

Article  PubMed  PubMed Central  Google Scholar 

Kyriacou A, Melson E, Chen W, Kempegowda P. Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus? Clin Med (Lond). 2020;20(4):417–23. https://doi.org/10.7861/clinmed.2020-0054.

Article  PubMed  Google Scholar 

Tachibana M, Imagawa A. Type 1 diabetes related to immune checkpoint inhibitors. Best Pract Res Clin Endocrinol Metab. 2022;36(3):101657. https://doi.org/10.1016/j.beem.2022.101657.

Article  CAS  PubMed  Google Scholar 

Imagawa A. Two types of fulminant type 1 diabetes mellitus: Immune checkpoint inhibitor-related and conventional. J Diabetes Investig. 2021;12(6):917–9. https://doi.org/10.1111/jdi.13450.

Article  PubMed  Google Scholar 

Baden MY, Imagawa A, Abiru N, Awata T, Ikegami H, Uchigata Y, et al. Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy. Diabetol Int. 2018;10(1):58–66. https://doi.org/10.1007/s13340-018-0362-2.

Article  PubMed  PubMed Central  Google Scholar 

Hanafusa T, Imagawa A. Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Pract Endocrinol Metab. 2007;3(1):36–45. https://doi.org/10.1038/ncpendmet0351.

Article  CAS  PubMed  Google Scholar 

Hirota H, Tsutsumi C, Kimata H, Watanabe D, Imbe H, Takamoto S, et al. A case of fulminant type 1 diabetes patient accompanied by hyperinsulinemic hypoglycemia prior to clinical diagnosis of diabetes (in Japanese). J Japan Diab Soc. 2016;59(4):210–7. https://doi.org/10.11213/tonyobyo.59.210.

Article  Google Scholar 

Miyagahara T, Fujimori N, Oono T, Okamoto M, Sato N, Sonoda N, et al. Fulminant type 1 diabetes mellitus following acute pancreatitis and hypoglycemia with sequential imaging of the pancreas using computed tomography: a case report (in Japanese). J Japan Soc Gastroenterol. 2019;116(2):161–7. https://doi.org/10.11405/nisshoshi.116.161.

Article  Google Scholar 

Imagawa A, Hanafusa T. Fulminant type 1 diabetes mellitus. Endocr J. 2006;53(5):577–84. https://doi.org/10.1507/endocrj.kr-72.

Article  CAS  PubMed  Google Scholar 

Chen YN, Zhao MW, Cui J, Yao HB. Acute pancreatitis may be a pathogenic factor of fulminant type 1 diabetes mellitus. Chin Med J (Engl). 2020;134(9):1127–8. https://doi.org/10.1097/CM9.0000000000001274.

Article  CAS  PubMed  Google Scholar 

Matsuura N, Yoshino S, Morisaki H. A case of fulminant type 1 diabetes masquerading acute pancreatitis. J Gen Fam Med. 2017;18(1):32–4. https://doi.org/10.1002/jgf2.12.

Article  PubMed  PubMed Central  Google Scholar 

Onuma H, Tohyama M, Imagawa A, Hanafusa T, Kobayashi T, Kano Y, et al. High frequency of HLA B62 in fulminant type 1 diabetes with the drug-induced hypersensitivity syndrome. J Clin Endocrinol Metab. 2012;97:E2277–81. https://doi.org/10.1210/jc.2012-2054.

Article  CAS  PubMed  Google Scholar 

Pharmaceuticals and Medical Devices Agency website https://www.info.pmda.go.jp/fsearchnew/jsp/menu_fukusayou_base.jsp Accessed 29 July 2024

Sekine N, Motokura T, Oki T, Umeda Y, Sasaki N, Hayashi M, et al. Rapid loss of insulin secretion in a patient with fulminant type 1 diabetes mellitus and carbamazepine hypersensitivity syndrome. JAMA. 2001;285(9):1153–4. https://doi.org/10.1001/jama.285.9.1153.

Article  CAS  PubMed  Google Scholar 

Ichikawa T, Kitae A, Takeda S, Sueyoshi A, Hamaguchi M, Fukui M. Transition of blood glucose level in a patient with pregnancy-associated fulminant type 1 diabetes mellitus. J Diabetes Investig. 2021;12(5):894–6. https://doi.org/10.1111/jdi.13419.

Article  PubMed  Google Scholar 

Takeuchi Y, Kawasaki M, Sato F, Sakurada M, Nishida K, Honda I, et al. A case of fulminant type 1 diabetes occurred in the treatment for gestational diabetes (in Japanese). J Japan Diab Soc. 2021;64(9):487–92. https://doi.org/10.11213/tonyobyo.64.487.

Article  Google Scholar 

Egashira F, Kawashima M, Morikawa A, Kosuda M, Ishihara H, Watanabe K. A rare case of fulminant type 1 diabetes mellitus accompanied by both acute pancreatitis and myocarditis-case report. BMC Endocr Disord. 2020;20(1):127. https://doi.org/10.1186/s12902-020-00607-3.

Article  PubMed  PubMed Central  Google Scholar 

Matsuo T, Ushiroda Y. Fatty liver formation in fulminant type 1 diabetes. Endocrinol Diabetes Metab Case Rep. 2015;2016:15–0121. https://doi.org/10.1530/EDM-15-0121.

Article  PubMed  Google Scholar 

Imagawa A. Immune checkpoint inhibitor-related onset of fulminant type 1 diabetes mellitus: pathophysiology and characteristics (in Japanese). Diabetol Endocrinol Metabol. 2023;57(4):410–7.

Google Scholar